Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical alzheimer’s disease

Journal of Neuroscience

Volumn 35, Issue 29, 2015, Pages 10402-10411

  Besson, Florent L ^a,b,c   Joie, Renaud La ^a,b,c,d   Doeuvre, Loïc ^a,b,c,d   Gaubert, Malo ^a,b,c,d   Mézenge, Florence ^a,b,c,d   Egret, Stéphanie ^a,b,c,d   Landeau, Brigitte ^a,b,c,d   Barré, Louisa ^b   Abbas, Ahmed ^a,b,c,d   Ibazizene, Meziane ^b   de La Sayette, Vincent ^a,b,c,d   Desgranges, Béatrice ^a,b,c,d   Eustache, Francis ^a,b,c,d   Chételat, Gaël ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

^d PSL RESEARCH UNIVERSITY   (France)

Author keywords

Alzheimer s disease; Amyloid; Biomarkers; FDG; MRI; PET

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; FLUORODEOXYGLUCOSE; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; FEMALE; HUMAN; MALE; NEOCORTEX; NERVE DEGENERATION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREFRONTAL CORTEX; PRIORITY JOURNAL; VOXEL BASED MORPHOMETRY; BRAIN; COMPUTER ASSISTED DIAGNOSIS; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MULTIMODAL IMAGING; PATHOLOGY; PLAQUE, AMYLOID; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MULTIMODAL IMAGING; NERVE DEGENERATION; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY;

EID: 84937687757     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0150-15.2015     Document Type: Article

References (59)

1. Alexopoulos P, Kriett L, Haller B, Klupp E, Gray K, Grimmer T, Laskaris N, Förster S, Perneczky R, Kurz A, Drzezga A, Fellgiebel A, Yakushev I (2014) Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease. Alzheimers Dement 10:684-689. CrossRef Medline
2. Arenaza-Urquijo EM, Landeau B, La Joie R, Mevel K, Mézenge F, Perrotin A, Desgranges B, Bartrés-Faz D, Eustache F, Chételat G (2013) Relationships between years of education and gray matter volume, metabolism and functional connectivity in healthy elders. Neuroimage 83:450-457. CrossRef Medline
3. Arnett james A LSS (1995) Effect of physical layout in performance of the Trail Making Test. Psychological Assessment 7:220 -221. CrossRef
4. Barkhof F, Polvikoski TM, van Straaten EC, Kalaria RN, Sulkava R, Aronen HJ, Niinistö L, Rastas S, Oinas M, Scheltens P, Erkinjuntti T (2007) The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology 69:1521-1527. CrossRef Medline
5. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, et al. (2012) Dominantly Inherited Alzheimer Network Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367:795-804. CrossRef Medline
6. Bohnen NI, Djang DS, Herholz K, Anzai Y, Minoshima S (2012) Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med 53:59 -71. CrossRef Medline
7. Boxer AL, Boeve BF (2007) Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer Dis Assoc Disord 21:S79 -S87. CrossRef Medline
8. Chételat G (2013a) Alzheimer disease: Abeta-independent processesrethinking preclinical AD. Nat Rev Neurol 9:123-124. CrossRef Medline
9. Chételat G (2013b) Reply: the amyloid cascade is not the only pathway to AD. Nat Rev Neurol 9:356. Medline
10. Chételat G, Desgranges B, de la Sayette V, Viader F, Berkouk K, Landeau B, Lalevée C, Le Doze F, Dupuy B, Hannequin D, Baron JC, Eustache F (2003) Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain 126:1955-1967. CrossRef Medline
11. Chételat G, Desgranges B, Landeau B, Mézenge F, Poline JB, de la Sayette V, Viader F, Eustache F, Baron JC (2008) Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 131:60 -71. Medline
12. Chételat G, Villain N, Desgranges B, Eustache F, Baron JC (2009) Posterior cingulate hypometabolism in early Alzheimer's disease: what is the contribution of local atrophy versus disconnection? Brain 132:e133; author reply e134. CrossRef Medline
13. Chételat G, La Joie R, Villain N, Perrotin A, de La Sayette V, Eustache F, Vandenberghe R (2013) Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin 2:356 -365. CrossRef Medline
14. de Souza LC, Chupin M, Bertoux M, Lehéricy S, Dubois B, Lamari F, Le Ber I, Bottlaender M, Colliot O, Sarazin M (2013) Is hippocampal volume a good marker to differentiate Alzheimer's disease from frontotemporal dementia? J Alzheimers Dis 36:57-66. Medline
15. Dritschel BH, Williams JM, Baddeley AD, Nimmo-Smith I (1992) Autobiographical fluency: a method for the study of personal memory. Mem Cognit 20:133-140. CrossRef Medline
16. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, et al. (2014) Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13:614-629. CrossRef Medline
17. Eustache F, Desgranges B, Lalevée C (1998) [Clinical evaluation of memory]. Rev Neurol 154:S18 -S32. Medline
18. Fjell AM, Walhovd KB (2012) Neuroimaging results impose new views on Alzheimer's disease-the role of amyloid revised. Mol Neurobiol 45:153- 172. CrossRef Medline
19. Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gutierrez Gomez M, Langois CM, Langbaum JB, Roontiva A, Thiyyagura P, Lee W, Ayutyanont N, Lopez L, Moreno S, Muñoz C, Tirado V, Acosta-Baena N, Fagan AM, Giraldo M, Garcia G, Huentelman MJ, et al. (2015) Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.JAMANeurol 72:316- 324. CrossRef Medline
20. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189 -198. CrossRef Medline
21. Fotuhi M, Do D, Jack C (2012) Modifiable factors that alter the size of the hippocampus with ageing. Nat Rev Neurol 8:189 -202. Medline
22. Fouquet M, Desgranges B, La Joie R, Rivière D, Mangin JF, Landeau B, Mézenge F, Pélerin A, de La Sayette V, Viader F, Baron JC, Eustache F, Chételat G (2012) Role of hippocampal CA1 atrophy in memory encoding deficits in amnestic Mild Cognitive Impairment. Neuroimage 59:3309 -3315. CrossRef Medline
23. Fouquet M, Besson FL, Gonneaud J, La Joie R, Chételat G (2014) Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan. Neuropsychol Rev 24:290 -299. CrossRef Medline
24. Geuze E, Vermetten E, Bremner JD (2005) MR-based in vivo hippocampal volumetrics. 2. Findings in neuropsychiatric disorders. Mol Psychiatry 10:160 -184. CrossRef Medline
25. Grober EBH (1987) Genuine memory deficits in dementia. Developmental Neuropsychology 3:13-36. CrossRef
26. Jack CR Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ, Roberts RO, Rocca WA, Boeve BF, Petersen RC (2012) An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71:765-775. CrossRef Medline
27. Jack CR Jr, Wiste HJ, Weigand SD, Knopman DS, Lowe V, Vemuri P, Mielke MM, Jones DT, Senjem ML, Gunter JL, Gregg BE, Pankratz VS, Petersen RC (2013) Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 81:1732-1740. CrossRef Medline
28. Jack CR Jr, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, Lowe VJ, Senjem ML, Gunter JL, Preboske GM, Pankratz VS, Vemuri P, Petersen RC (2014) Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol 13:997-1005. CrossRef Medline
29. Jagust W (2013) Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron 77:219 -234. CrossRef Medline
30. Jagust WJ, Landau SM; Alzheimer's Disease Neuroimaging Initiative (2012) Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci 32:18227-18233. CrossRef Medline
31. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, Mathis CA; Alzheimer's Disease Neuroimaging Initiative (2009) Relationships between biomarkers in aging and dementia. Neurology 73:1193-1199. CrossRef Medline
32. Kalpouzos G, Chételat G, Baron JC, Landeau B, Mevel K, Godeau C, Barré L, Constans JM, Viader F, Eustache F, Desgranges B (2009) Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol Aging 30:112-124. CrossRef Medline
33. Koechlin E, Summerfield C (2007) An information theoretical approach to prefrontal executive function. Trends Cogn Sci 11:229 -235. CrossRef Medline
34. La Joie R, Perrotin A, Barré L, Hommet C, Mézenge F, Ibazizene M, Camus V, Abbas A, Landeau B, Guilloteau D, de La Sayette V, Eustache F, Desgranges B, Chételat G (2012) Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimer's disease dementia. J Neurosci 32:16265-16273. CrossRef Medline
35. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative (2011) Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 32:1207-1218. CrossRef Medline
36. Lezak M (1995) Neuropsychological assessment. Oxford: OUP.
37. Lezak MD, Howieson DB, Bigler ED, Tranel D (2004) Neuropsychological assessment (4th ed). New York: OUP.
38. Matthis S (1976) Mental status examination for organic mental syndrome in the elderly patients. In: Geriatric psychiatry: a handbook for psychia- trists and primary care physicians (Bellak L, Karasu T, eds), pp 77-121. New York: Grune and Stratton.
39. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:263-269. CrossRef Medline
40. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939- 944. CrossRef Medline
41. Mevel K, Landeau B, Fouquet M, La Joie R, Villain N, Mézenge F, Perrotin A, Eustache F, Desgranges B, Chételat G (2013) Age effect on the default mode network, inner thoughts, and cognitive abilities. Neurobiol Aging 34:1292-1301. CrossRef Medline
42. Mormino EC, Betensky RA, Hedden T, Schultz AP, Amariglio RE, Rentz DM, Johnson KA, Sperling RA (2014) Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 71:1379 -1385. CrossRef Medline
43. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67:122-131. CrossRef Medline
44. Nestor PJ, Fryer TD, Smielewski P, Hodges JR (2003) Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 54:343-351. CrossRef Medline
45. Park DC, Lautenschlager G, Hedden T, Davidson NS, Smith AD, Smith PK (2002) Models of visuospatial and verbal memory across the adult life span. Psychol Aging 17:299 -320. CrossRef Medline
46. Piolino P (2003) Autobiographical memory in aging. Psychol Neuropsychiatr Vieil 1:25-35. Medline
47. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, Fagan AM, Shah AR, Alvarez S, Arbelaez A, Giraldo M, Acosta-Baena N, Sperling RA, Dickerson B, Stern CE, Tirado V, Munoz C, Reiman RA, Huentelman MJ, Alexander GE, et al. (2012) Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a casecontrol study. Lancet Neurol 11:1048 -1056. CrossRef Medline
48. Signoret J (1991) Batterie d'efficience mnésique BEM 144 [book in French]. Paris: Elsevier.
49. Small SA, Duff K (2008) Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 60:534 -542. CrossRef Medline
50. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, et al. (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:280 -292. CrossRef Medline
51. Stuss DT, Alexander MP (2000) Executive functions and the frontal lobes: a conceptual view. Psychol Res 63:289 -298. CrossRef Medline
52. Villain N, Desgranges B, Viader F, de la Sayette V, Mézenge F, Landeau B, Baron JC, Eustache F, Chételat G (2008) Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease. J Neurosci 28:6174-6181. CrossRef Medline
53. Villain N, Fouquet M, Baron JC, Mézenge F, Landeau B, de La Sayette V, Viader F, Eustache F, Desgranges B, Chételat G (2010) Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. Brain 133:3301-3314. CrossRef Medline
54. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 12:357-367. CrossRef Medline
55. Wechsler D (1997) Wechsler Adult Intelligence Scale, Ed 3. San Antonio, TX: The Psychological Corporation.
56. Whitwell JL, Josephs KA (2011) Neuroimaging in frontotemporal lobar degeneration- predicting molecular pathology. Nat Rev Neurol 8:131-142. Medline
57. Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ (2013a) Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-amyloid in cognitively normal older individuals. J Neurosci 33:5553-5563. CrossRef Medline
58. Wirth M, Oh H, Mormino EC, Markley C, Landau SM, Jagust WJ (2013b) The effect of amyloid beta on cognitive decline is modulated by neural integrity in cognitively normal elderly. Alzheimers Dement 9:687-698.e1. CrossRef Medline
59. Wirth M, Villeneuve S, Haase CM, Madison CM, Oh H, Landau SM, Rabinovici GD, Jagust WJ (2013c) Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 70:1512-1519. Medline